We are live on ! Find out more
TMO icon

Thermo Fisher Scientific

2,488 hedge funds and large institutions have $188B invested in Thermo Fisher Scientific in 2023 Q4 according to their latest regulatory filings, with 290 funds opening new positions, 884 increasing their positions, 984 reducing their positions, and 132 closing their positions.

New
Increased
Maintained
Reduced
Closed

120% more first-time investments, than exits

New positions opened: 290 | Existing positions closed: 132

18% more call options, than puts

Call options by funds: $1.92B | Put options by funds: $1.64B

9% more capital invested

Capital invested by funds: $173B → $188B (+$15.2B)

5% more funds holding

Funds holding: 2,3652,488 (+123)

3.27% more ownership

Funds ownership: 88.54%91.82% (+3.3%)

1% more funds holding in top 10

Funds holding in top 10: 139141 (+2)

10% less repeat investments, than reductions

Existing positions increased: 884 | Existing positions reduced: 984

Holders
2,488
Holders Change
+123
Holders Change %
+5.2%
% of All Funds
36.27%
Holding in Top 10
141
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+1.44%
% of All Funds
2.06%
New
290
Increased
884
Reduced
984
Closed
132
Calls
$1.92B
Puts
$1.64B
Net Calls
+$287M
Net Calls Change
+$314M
Name Holding Trade Value Shares
Change
Change in
Stake
TSM
826
Two Star Manager
Florida
$5.56M +$5.07M +10,466 New
PCM
827
Palisade Capital Management
New Jersey
$5.55M +$11.1K +23 +0.2%
RMCM
828
Reynders McVeigh Capital Management
Massachusetts
$5.55M -$356K -735 -7%
HEIP
829
Hudson Edge Investment Partners
New Jersey
$5.53M +$381K +788 +8%
WAM
830
Wilson Asset Management
Australia
$5.51M
UF
831
Univest Financial
Pennsylvania
$5.5M -$139K -287 -3%
GH
832
GAM Holding
Switzerland
$5.48M -$2.09M -4,319 -29%
PAM
833
Panagora Asset Management
Massachusetts
$5.45M
PCA
834
Providence Capital Advisors
North Carolina
$5.41M +$2.9K +6 +0.1%
CCG
835
Cloverfields Capital Group
Minnesota
$5.41M +$4.93M +10,191 New
CA
836
Cetera Advisors
Colorado
$5.37M +$346K +714 +8%
BMCM
837
Bryn Mawr Capital Management
Pennsylvania
$5.37M +$602K +1,243 +14%
CGIM
838
Capital Group Investment Management
Singapore
$5.36M -$227K -470 -4%
PCA
839
Pallas Capital Advisors
Massachusetts
$5.36M -$729K -1,506 -13%
FC
840
FORA Capital
Florida
$5.35M -$2.61M -5,394 -35%
AMCA
841
Arthur M. Cohen & Associates
Illinois
$5.35M +$47.9K +99 +1%
KPWS
842
Kestra Private Wealth Services
Texas
$5.31M +$623K +1,288 +15%
PHP
843
Parkman Healthcare Partners
Connecticut
$5.31M -$2.58M -5,332 -35%
FI
844
FJ Investments
Utah
$5.31M +$4.84M +10,000 New
SNB
845
Security National Bank
Nebraska
$5.3M +$127K +263 +3%
PA
846
Procyon Advisors
Connecticut
$5.28M -$326K -673 -6%
AF
847
Arrow Financial
New York
$5.26M -$16.5K -34 -0.3%
SEEDPG
848
S.E.E.D. Planning Group
New York
$5.21M +$243K +503 +5%
AWM
849
Apollon Wealth Management
South Carolina
$5.2M +$516K +1,067 +12%
RWA
850
River Wealth Advisors
Pennsylvania
$5.15M -$101K -208 -2%

TMO Hedge Fund Activity: Q4 2023 in Review

2,488 of the 6,860 institutional investors tracked by Wall St. Rank reported a position in Thermo Fisher Scientific (TMO) for Q4 2023, worth a combined $188B — up 8.8% from $173B a quarter earlier.

Buyers outnumbered sellers: 290 funds opened new TMO positions and 132 closed out — a net gain of 158 holders — while 884 added to existing stakes and 984 trimmed.

The largest buyer was Morgan Stanley, adding an estimated $6.14B. The largest seller was Massachusetts Financial Services, cutting an estimated $1.08B.

  • 2,488 institutional investors held Thermo Fisher Scientific (TMO) as of Q4 2023, up from 2,365 in Q3 2023.
  • Funds reported $188B of Thermo Fisher Scientific stock for Q4 2023, up 8.8% quarter-over-quarter.
  • 290 funds opened new Thermo Fisher Scientific positions in Q4 2023 and 132 closed out, a net change of +158 holders.
  • The largest Thermo Fisher Scientific buyer in Q4 2023 was Morgan Stanley, an estimated $6.14B added.
  • The largest Thermo Fisher Scientific seller in Q4 2023 was Massachusetts Financial Services, an estimated $1.08B sold.

Based on aggregated 13F filings for Q4 2023.